Clinical Trials Bristol-Myers Squibb invested $3.9 billion in 2012 to discover and develop innovative medicines to help patients prevail against serious diseases.
In the past several years, we have delivered a number of new products for patients in need, including medicines for rheumatoid arthritis, hepatitis B, cancer, HIV/AIDS and diabetes. As we look to the future, our pipeline
continues to expand as we have more than 60 investigational compounds in development, of which, about one-third are biologics. Below is a list of the therapeutic areas we concentrate in:
In the true spirit of science, we are dedicated to educating and sharing our clinical trials information and data with patients, medical/research communities, the media, policy makers and the general public. We act on our belief that the priceless ingredient of every product is the integrity of its maker.